Developing therapeutic monoclonal antibodies at pandemic pace

Nat Biotechnol. 2020 May;38(5):540-545. doi: 10.1038/s41587-020-0512-5.

Abstract

The time from discovery to proof-of-concept trials could be reduced to 5–6 months from a traditional timeline of 10–12 months.

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Viral / therapeutic use*
  • Clinical Trials as Topic
  • Drug Development / methods*
  • Drug Development / standards
  • Humans
  • Pandemics
  • Technology, Pharmaceutical
  • Time Factors
  • Virus Diseases / drug therapy*
  • Virus Diseases / epidemiology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Viral